Publicaciones en colaboración con investigadores/as de Universidad Autónoma de Madrid (24)

2023

  1. Control of a hippocampal recurrent excitatory circuit by cannabinoid receptor-interacting protein Gap43

    Nature Communications, Vol. 14, Núm. 1

  2. Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

    Nature Communications, Vol. 14, Núm. 1

2019

  1. Therapeutic targeting of HER2–CB 2 R heteromers in HER2-positive breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 9, pp. 3863-3872

  2. Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116)

    Proceedings of the National Academy of Sciences of the United States of America

2018

  1. Pathway-specific control of striatal neuron vulnerability by corticostriatal cannabinoid CB 1 receptors

    Cerebral Cortex, Vol. 28, Núm. 1, pp. 307-322

  2. Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum

    Neuropsychopharmacology, Vol. 43, Núm. 5, pp. 964-977

2017

  1. Loss of Cannabinoid CB1 Receptors Induces Cortical Migration Malformations and Increases Seizure Susceptibility

    Cerebral Cortex, Vol. 27, Núm. 11, pp. 5303-5317

2016

  1. MicroRNA let-7d is a target of cannabinoid CB 1 receptor and controls cannabinoid signaling

    Neuropharmacology, Vol. 108, pp. 345-352

  2. Anticancer mechanisms of cannabinoids

    Current Oncology, Vol. 23, pp. S23-S32

  3. Sustained Gq-protein signaling disrupts striatal circuits via JNK

    Journal of Neuroscience, Vol. 36, Núm. 41, pp. 10611-10624

2015

  1. TRIB3 suppresses tumorigenesis by controlling mTORC2/AKT/FOXO signaling

    Molecular and Cellular Oncology, Vol. 2, Núm. 3

  2. The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway

    Cell Death and Differentiation, Vol. 22, Núm. 10, pp. 1618-1629

2014

  1. A restricted population of CB1 cannabinoid receptors with neuroprotective activity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262

  2. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling

    Journal of Biological Chemistry, Vol. 289, Núm. 32, pp. 21960-21972

  3. Tocilizumab en pacientes con artritis reumatoide activa y respuesta inadecuada a fármacos antirreumáticos modificadores de la enfermedad o antagonistas del factor de necrosis tumoral: Subanálisis de los datos españoles de un estudio abierto cercano a la práctica clínica habitual

    Reumatologia Clinica, Vol. 10, Núm. 2, pp. 94-100

2013

  1. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy

    Journal of Alzheimer's Disease, Vol. 35, Núm. 3, pp. 525-539

  2. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas

    Oncogene, Vol. 32, Núm. 20, pp. 2534-2542

2011

  1. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

    Brain, Vol. 134, Núm. 1, pp. 119-136

2010

  1. A New Age for MAGL

    Chemistry and Biology

  2. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

    Molecular Cancer, Vol. 9